Aminophylline: Nursing Drug Guide, Theophylline Toxicity & Monitoring
IV methylxanthine bronchodilator with a narrow therapeutic window: serum theophylline above 20 mcg/mL can trigger seizures and arrhythmias. Stop the infusion for repetitive vomiting, draw levels per label schedule, and escalate toxicity with supportive care—not a single antidote.
Aminophylline delivers theophylline on a narrow therapeutic index. At serum theophylline concentrations above 20 mcg/mL, adverse reactions escalate—including persistent repetitive vomiting, cardiac arrhythmias, and intractable seizures that can be lethal. Labeling directs nurses to stop the IV infusion whenever repetitive vomiting or other toxicity signs appear (even if another cause is suspected) and obtain a serum theophylline level immediately. Target average steady-state concentrations are 10–15 mcg/mL.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every rate change, confirm recent methylxanthine exposure, interacting drugs, and the latest serum level. If the patient vomits repeatedly or shows new tremor, tachycardia, or confusion—stop the infusion, draw a level, and notify the prescriber/pharmacist. Never increase the infusion rate when toxicity signs are present.
Most common brand names
Aminophylline is the ethylenediamine salt of theophylline (approximately 79% anhydrous theophylline by weight). It is supplied generically as an IV solution.
Common presentation: Aminophylline Injection, USP — 25 mg/mL (equivalent to 19.7 mg/mL anhydrous theophylline). Reconcile all methylxanthine sources before loading doses.
Why we give it — Indications
IV theophylline (as aminophylline) is an adjunct to inhaled beta-2 agonists and systemic corticosteroids for acute exacerbations of reversible airflow obstruction in asthma, emphysema, and chronic bronchitis. Inhaled albuterol and prednisone remain first-line for many exacerbations; IV aminophylline is added only when prescriber and protocol support methylxanthine therapy.
How it works
Theophylline relaxes bronchial smooth muscle and suppresses airway hyperresponsiveness. Adverse effects such as tachycardia, headache, and emesis increase when serum concentrations exceed 20 mcg/mL. Clinically important bronchodilation usually requires levels above 10 mcg/mL.
Dosing overview
Concentration: 25 mg/mL aminophylline (≈19.7 mg/mL anhydrous theophylline).
Toxicity: Serum theophylline >20 mcg/mL — stop infusion for repetitive vomiting; measure levels per label schedule.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Therapeutic range | 10–15 mcg/mL average | Individual clearance varies widely |
| Half-life adults | ~8.7 h nonsmokers | Recheck after one half-life when starting infusion |
| Half-life children | ~3.4 h (ages 1–9) | More frequent monitoring when initiating |
| Protein binding | Reduced in cirrhosis | Total level may underestimate toxicity |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm methylxanthine exposure in the last 24 hours before any loading dose; obtain a serum theophylline level first if the patient has received theophylline recently
- Complete medication reconciliation for interacting drugs and recent smoking status changes
- Review heart failure, hepatic disease, seizure history, fever, and pregnancy trimester (third trimester reduces clearance per labeling)
- Verify ideal body weight for mg/kg calculations; aminophylline distributes poorly into fat
Contraindications
- Hypersensitivity to theophylline or other product components, including ethylenediamine
- Do not give a loading dose when the serum theophylline concentration is already ≥10 mcg/mL without prescriber/pharmacist guidance
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Erythromycin / macrolides | Decreased theophylline clearance; higher levels | Flag new macrolide orders; expect more frequent level monitoring and possible rate reduction |
| Ciprofloxacin / fluoroquinolones | Decreased clearance | Notify pharmacist when fluoroquinolone starts or stops during infusion |
| Cimetidine | Decreased clearance | Anticipate lower infusion requirements; monitor levels after H2 blocker changes |
| Rifampin (if started/stopped) | Increased clearance when inducing; accumulation when discontinued | Reconcile TB or other therapy changes; redraw levels after interaction begins or ends |
On a small screen, swipe or scroll sideways to see the full table.
The prescribing information lists many additional interacting drugs; consult current labeling and pharmacy before new orders.
Administration
- Loading: 5.7 mg/kg aminophylline over 30 minutes when no theophylline in prior 24 h
- Maintenance via IV infusion pump setup with high-alert medication administration double-check
Expected therapeutic response
- Improved air entry; decreased shortness of breath
- Serum theophylline trending toward 10–15 mcg/mL average
Red flags — Stop and act
Adverse effects
| Adverse effect | When it matters | Nursing response |
|---|---|---|
| Nausea, vomiting, headache, insomnia | Usually mild when peak level <20 mcg/mL | Stop infusion for repetitive vomiting; obtain level; notify prescriber/pharmacist |
| Tremor, restlessness, irritability | Common methylxanthine CNS effects | Document; correlate with level; do not dismiss as anxiety alone |
| Sinus tachycardia, multifocal atrial tachycardia | More likely as levels rise; reported ≥15 mcg/mL in hypoxic COPD patients | Obtain ECG; hold infusion if toxicity suspected |
| Persistent vomiting, arrhythmias, intractable seizures | Peak level >20 mcg/mL per labeling | Stop infusion; emergency escalation; overdose pathway |
| Ethylenediamine hypersensitivity (rare) | Severe skin reactions after prior topical ethylenediamine exposure | Stop drug; allergy documentation; escalate per protocol |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Acute overdose (excessive loading or rate <24 h) and chronic overdosage (excessive maintenance >24 h) present differently. Chronic toxicity in patients >60 years can cause seizures, arrhythmias, and death at levels >30 mcg/mL even when peak levels appear lower than acute massive ingestions.
Early signs
- Repetitive vomiting, tremor, tachycardia, restlessness—may precede seizures
- Level >20 mcg/mL: increasing arrhythmia and seizure risk
- Level >30 mcg/mL during chronic overdosage: high risk of generalized seizures and hemodynamically unstable arrhythmias
Antidote
No single antidote. Labeling directs: stop the infusion; supportive care with IV access, airway support, and continuous ECG monitoring; aggressive anticonvulsant therapy with IV benzodiazepines (e.g., diazepam) and phenobarbital for theophylline-induced seizures (phenytoin is ineffective per label); multiple-dose oral activated charcoal when appropriate; extracorporeal removal when seizures or arrhythmias cannot be controlled.
Contact local poison control or medical toxicology services per facility protocol when level >30 mcg/mL, toxicity signs persist, or seizures occur. Serial levels every 2–4 hours guide therapy per labeling.
Look-alike / sound-alike and error prevention
- Aminophylline vs amiodarone — sound-alike antiarrhythmic confusion in verbal orders
- Aminophylline vs aminoglycosides — similar prefix in MAR lists; verify drug name and indication
- mg/kg aminophylline vs mg/kg theophylline — infusion rates differ (multiply theophylline rate by 0.8 for aminophylline, or use label conversion)
- Loading dose given when level already therapeutic — always check recent methylxanthine exposure and level before load
- Pump rate increases without level — labeling warns against increasing rate for symptom flare when level is not sub-therapeutic
- Duplicate methylxanthine therapy — oral theophylline plus IV aminophylline without level reconciliation
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Level timing | 30 min after loading dose; second level after one expected half-life when starting maintenance; then at 24-hour intervals per label |
| IV admixture | Do not mix aminophylline in a syringe with other drugs; avoid alkali-labile agents in same line per labeling |
| Piggyback | Turn off primary line during aminophylline if incompatibility risk exists |
| Caffeine | Patient caffeine intake can add to CNS stimulation; teach moderation unless prescriber approves |
| Commonly missed | Smoking cessation increasing levels; new macrolide/fluoroquinolone; fever slowing clearance |
| Ask pharmacy when | Unclear load vs maintenance, interaction added, cirrhosis/pregnancy with low protein binding, or level >20 mcg/mL |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Elderly (>60 years) | Reduced clearance and lower protein binding; greater sensitivity after chronic overdosage. Maximum infusion ordinarily 21 mg/hr aminophylline unless symptomatic with level <10 mcg/mL per labeling. |
| Hepatic impairment | Clearance decreased 50% or more in cirrhosis, acute hepatitis, or cholestasis—consider unbound level 6–12 mcg/mL when binding reduced. |
| Heart failure / cor pulmonale | Clearance reduced; initial rate should not exceed 21 mg/hr aminophylline without level monitoring at 24-hour intervals. |
| Seizure disorders | Use extreme caution; neurologic disease increases seizure risk at a given level compared with patients without underlying disease. |
| Neonates and infants <1 year | Immature metabolism; dosing and monitoring requirements differ—follow neonatal tables and specialist guidance. |
| Pregnancy | Pregnancy category C: no adequate controlled studies in humans. Third trimester reduces clearance—more intensive level monitoring required per labeling. |
| Lactation | Theophylline is excreted into breast milk at concentrations about equivalent to maternal serum. Serious infant effects are unlikely unless the mother has toxic maternal levels; monitor mother’s level and infant irritability per labeling and LactMed. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
- Serial serum theophylline per label; ECG if arrhythmia suspected
- Basic metabolic panel when prolonged therapy or toxicity
Patient teaching
- Report nausea, vomiting (especially repeated episodes), palpitations, tremor, restlessness, or confusion immediately—do not wait for the next scheduled level
- Explain that blood tests will be drawn on a schedule to keep theophylline in a safe range (about 10–15 mcg/mL average)
- Limit extra caffeine (coffee, energy drinks, tea) unless the prescriber approves; methylxanthines add together
- Tell the team about new antibiotics, smoking changes, or fever—these alter drug levels
- Do not take extra theophylline or aminophylline at home while receiving IV therapy unless specifically ordered
The Hold Rule
- Repetitive vomiting or other signs consistent with theophylline toxicity—even if another cause is suspected—stop infusion and obtain serum theophylline level immediately
- Serum theophylline >20 mcg/mL or prescriber/pharmacy hold parameter reached
- Known hypersensitivity to theophylline or ethylenediamine
- Unclear mg/kg loading dose, maintenance rate, or pump programming; no recent level before rate increase
- New generalized seizure, intractable vomiting, or hemodynamically unstable arrhythmia during infusion
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Build serum theophylline timing into handoff whenever an aminophylline infusion runs. Never increase the infusion rate for persistent bronchospasm when vomiting or rising levels suggest toxicity.
1. Check-before-you-give protocol
- Confirm patient identity, drug, concentration (25 mg/mL), route, and pump rate in mg/kg/hr aminophylline
- Verify methylxanthine exposure in the last 24 hours and most recent theophylline level
- Reconcile new antibiotics, smoking status, and hepatic/heart failure history
- Independent double-check for loading doses and rate changes
2. High-alert and safety badge
Narrow therapeutic index — high-alert IV therapyIndividual clearance varies fourfold; median population doses can be sub-therapeutic or toxic in a given patient. Levels are mandatory for safe titration.
3. Hold and question rules
- Stop infusion for repetitive vomiting before antiemetics alone
- Question any rate increase when the level is not sub-therapeutic (<10 mcg/mL) per labeling
- Escalate when level crosses 20 mcg/mL or seizure/arrhythmia occurs
4. Critical teach-back questions
- “What symptoms should you report right away?” Repetitive vomiting, tremor, palpitations, confusion.
- “Why are we drawing blood?” To keep theophylline in a safe range and prevent seizures or arrhythmias.
5. Care coordination
Pharmacy: Level interpretation, interaction checks, and infusion rate adjustments when clearance changes.
Respiratory / medical team: Coordinate with inhaled bronchodilators and steroids; reassess need for continued IV methylxanthine as symptoms improve.
🧠 Quick mental checklist
- Any theophylline in last 24 h?
- Latest level and next draw due?
- Vomiting, tremor, or confusion?
- New macrolide or fluoroquinolone?
- Pump rate double-checked in mg/kg/hr aminophylline?
Aminophylline NCLEX practice questions
Practice NCLEX-style clinical judgment practice for aminophylline using a tabbed inpatient case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), trend interpretation, matrix urgency sorting, level judgment, and overdose-management cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Aminophylline loading 5.7 mg/kg IV over 30 min — completed 0800 (68 kg → 388 mg)
- Aminophylline 0.5 mg/kg/hr IV continuous — started 0830 (34 mg/hr)
- Erythromycin 500 mg IV q8h — first dose 1000 today (interaction)
- Albuterol nebulizer q4h PRN; methylprednisolone IV daily
- 0830 (30 min post load): 14 mcg/mL
- 1600 (steady-state check): 19 mcg/mL
- 2200 repeat: 22 mcg/mL (pending notify)
- 2200: HR 118, BP 132/78, RR 22, SpO2 93% on 2 L NC, temp 37.1 °C
- Patient reports nausea; two episodes vomiting in last hour
- 74-year-old, 68 kg, acute asthma exacerbation, day 1
- 2145: Fine hand tremor noted; patient anxious
- 2210: Third vomitus in 1 h; infusion still running at ordered rate
Answer key & rationale
Frequently asked questions
What serum theophylline level is considered toxic?
At concentrations above 20 mcg/mL, adverse reactions increase—including persistent vomiting, arrhythmias, and intractable seizures. Target average steady-state concentrations are 10–15 mcg/mL per labeling.
When must a nurse stop an aminophylline infusion?
Stop whenever repetitive vomiting or other toxicity signs appear—even if another cause is suspected—and obtain a serum theophylline concentration immediately.
What is the target therapeutic theophylline range?
Maintaining average serum theophylline between 10 and 15 mcg/mL achieves most bronchodilator benefit while minimizing serious adverse events.
Is there a single antidote for theophylline overdose?
No. Management includes stopping the infusion, supportive care, activated charcoal, anticonvulsants for seizures per label, and extracorporeal removal when indicated. Contact local poison control / toxicology per facility protocol.
Why are older adults at higher risk?
Reduced clearance, lower protein binding, and greater sensitivity after chronic overdosage. Max infusion 21 mg/hr aminophylline in patients >60 y unless level <10 mcg/mL and symptomatic.
References
- U.S. National Library of Medicine. AMINOPHYLLINE injection — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6936595d-255f-0321-e053-2a91aa0a15f7
- Drugs and Lactation Database (LactMed). Theophylline. NIH.https://www.ncbi.nlm.nih.gov/books/NBK519008/
- National Heart, Lung, and Blood Institute. Asthma. NIH.https://www.nhlbi.nih.gov/health/asthma
- StatPearls. Theophylline toxicity. NCBI Bookshelf.https://www.ncbi.nlm.nih.gov/books/NBK482513/
- U.S. Food and Drug Administration. Drug interactions: what you should know.https://www.fda.gov/drugs/resources-drugs/drug-interactions-what-you-should-know
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.